Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]DBPR108 in Healthy Chinese Males
NCT05072028Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prusogliptin in type 2 diabetes mellitus (T2DM), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Total radioactivity in urine and feces, Peak plasma concentration and 3 more. Started Nov 2021; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05072028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072028.